Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma

Huang, Gloria S.; Chiu, Lydia G.; Gebb, Juliana; Gunter, Marc J.; Sukumvanich, Paniti; Goldberg, Gary L.; Einstein, Mark H.

doi:10.1016/j.ygyno.2007.08.060

Cited by 59 publications

(39 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The presenting symptom of this neoplasm often was abnormal uterine bleeding in post-menopause (40.9%) [15] , even if the patients frequently were asymptomatic (54.5%) [21] . In the literature [22] increased CA-125 serum levels have also been reported to be associated with the disease. In our study we found 18.2% patients with an increased CA-125 level.…”

Section: Discussionmentioning

confidence: 98%

Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases

et al. 2017

View full text Add to dashboard Cite

Objectives: The aim of our study was to evaluate the clinicopathological features and prognostic factors of uterine carcinosarcoma. Patients and Methods: In this retrospective study, the clinical characteristics of 44 patients with uterine MMMT were evaluated. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. Results: Forty-four patients with uterine carcinosarcoma were referred to our unit between 1995 and 2015. Their median age was 66.5 years. All women underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Twenty-five percent had omental resection. Pelvic lymphadenectomy was performed in 18.2% of the cases. Twenty-six of the patients presented with stage I/II disease, 17 with advanced stages. In 20.5% of the cases there were metastases at diagnosis. Forty women received adjuvant chemotherapy, with complete remission in 67.9% of the cases. Recurrences were observed in 27.3% of the women. Disease-free and overall survival was 27 and 103 months, respectively. The FIGO stage, histological type, tumour size, chemotherapy regimen, pelvic lymphadenectomy, and myometrial invasion did not affect survival. Conclusions: Uterine MMMT is an aggressive tumour, often diagnosed at an advanced stage and with a high rate of metastases or recurrences. Because of its rarity, its management is controversial and fixed prognostic factors cannot be defined.

show abstract

Section: Discussionmentioning

confidence: 98%

Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases

et al. 2017

View full text Add to dashboard Cite

show abstract

“…For example, in a retrospective study of 54 patients, a CA-125 value above 30 U/ml was significantly associated with deep myometrial invasion (61% vs. only 39% in patients with CA-125 below 30 U/ml) as well as higher disease stage (62% vs. only 38%) [8]. …”

Section: Diagnosismentioning

confidence: 99%

Uterine Carcinosarcomas - Diagnosis and Management

Denschlag

Ulrich

2018

Oncol Res Treat

View full text Add to dashboard Cite

Uterine carcinosarcomas are rare tumors that account for less than 5% of all uterine malignancies. These tumors (previously called malignant mixed Müllerian tumors) are dedifferentiated carcinomas that comprise carcinomatous and sarcomatous elements and arise from a single malignant clone. They are considered a high-risk variant of endometrial adenocarcinoma because carcinosarcomas share more similarities in epidemiology, risk factors, and clinical behavior with endometrial carcinoma than with uterine sarcomas. The clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma will be discussed in this review.

show abstract

“…In this study, the preoperative detection of the serum CA125 level was performed only in 43 patients (57.3%), and in patients with stage III and IV disease, the mean CA125 level was higher than in patients with stage I disease. A significantly elevated preoperative CA125 level was associated with the presence of extrauterine disease and late disease stage [16]. However, the majority of late stage cases did not exhibit preoperative elevated CA125 levels.…”

Section: Ultrasonographic Characteristicsmentioning

confidence: 87%

“…More recently, the potential utility of CA125 measurement has been evaluated in endometrial cancer patients. Several investigators have found that elevated levels of preoperative CA125 in patients with endometrial cancer (including UCS) are associated with pathologic risk factors such as high tumor grade, deep myometrial invasion, lymphovascular involvement, extrauterine disease, and nodal metastases [16][17][18]. In this study, the preoperative detection of the serum CA125 level was performed only in 43 patients (57.3%), and in patients with stage III and IV disease, the mean CA125 level was higher than in patients with stage I disease.…”

Section: Ultrasonographic Characteristicsmentioning

confidence: 99%

Ultrasonographic Findings of Uterine Carcinosarcoma

Zhao

Zhang

et al. 2018

Gynecol Obstet Invest

View full text Add to dashboard Cite

Aims: The aim of this study was to investigate the clinical features and ultrasonographic findings of uterine carcinosarcoma (UCS). Methods: Seventy-five patients (mean age, 58.6 years) with pathologically proven UCS who were treated at our hospital from January 2003 to December 2015 were retrospectively recruited. The clinical features and preoperative findings on transvaginal sonography (TVS) were investigated. Results: Eighty percent of the patients were postmenopausal. The primary symptoms were postmenopausal abnormal uterine bleeding (57.3%), irregular menstruation (18.7%), vaginal discharge (10.7%) and the presence of a uterine mass or others (13.3%). The tumor marker CA125 was evaluated in 43 women and was found to be elevated in 15 (34.9%); in 60% of those women (9/15), the CA125 level was lower than 200U/ml. According to the frequency of the different types of lesions observed by ultrasonic imaging, we decided to categorize the lesions into 3 different groups as follows: Group I, intrauterine tumors (73.33%); group II, intra-myometrial tumors (13.33%); and group III, intra-endometrial tumors (13.33 %). Conclusion: Combined with the clinical features, the characteristics demonstrated by TVS provide evidence for an indication of the presence of UCS and could contribute to clinical decision-making.

show abstract

Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma

Cited by 59 publications

References 34 publications

Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases

Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases

Uterine Carcinosarcomas - Diagnosis and Management

Ultrasonographic Findings of Uterine Carcinosarcoma

Contact Info

Product

Resources

About